Cas:301334-95-2 3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid manufacturer & supplier

We serve Chemical Name:3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid CAS:301334-95-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid

Chemical Name:3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid
CAS.NO:301334-95-2
Synonyms:3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid
Molecular Formula:C21H22N2O5
Molecular Weight:382.41000
HS Code:2933399090

Physical and Chemical Properties:
Melting point:204ºC
Boiling point:591.4ºC at 760mmHg
Density:1.286g/cm3
Index of Refraction:1.633
PSA:95.59000
Exact Mass:382.15300
LogP:4.67340

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid Use and application,3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid technical grade,usp/ep/jp grade.


Related News: China considers self-ruled Taiwan to be part of its territory and has long sought to limit its diplomatic relations and recognition at international bodies such as the W.H.O. 3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid manufacturer The FDA regulates cosmetics, but the cosmetics industry itself is responsible for assessing the health and safety of ingredient, and there’s not much FDA oversight of that process,” Bruton said.
The Personal Care Products Council, which represents the cosmetics industry, did not have comment on the findings.
A new study finds that many mass shooters in America suffered from a mental illness that wasn’t being treated when they committed their crime.
“Without losing sight of the larger perspective that most who are violent are not mentally ill, and most of the mentally ill are not violent, our message is that mental health providers, lawyers and the public should be made aware that some unmedicated patients do pose an increased risk of violence,” wrote researchers led by Dr. Ira Glick, from Stanford University’s School of Medicine.
Glick’s team studied 35 mass shooting cases that occurred in the United States between 1982 and 2019 and involved shooters who survived and were brought to trial.
Analysis of various sources of medical evidence on the mass shooters showed that 28 had mental illness diagnoses. Eighteen had schizophrenia and 10 had other diagnoses including bipolar disorder, delusional disorder, personality disorders and substance-related disorders.
Of the 28 shooters with a mental illness diagnosis, none were medicated or received other treatment for their disorders prior to their crimes, according to the study published recently in the Journal of Clinical Psychopharmacology.
Glick and his colleagues also examined 20 mass shooters who died at the crime scene and found that eight had schizophrenia, seven had other mental health diagnoses, and five had unknown diagnoses. None were receiving appropriate medications.
The investigators pointed out that despite the high frequency of mass shooting events in the United States, there has been almost no medical research on the nature and incidence of mental illness among people who commit these crimes.
“The psychiatric disorders seen in perpetrators of mass shootings are serious brain illnesses — as much in need of proper diagnosis and treatment as heart disease or any other medical condition,” the authors noted in a Stanford news release.
“We need to reduce the stigma associated with these diseases to enable patients to receive appropriate and adequate psychiatric medication and other treatments,” they added, “by actually talking to patients and their significant others, we have the opportunity to save lives. 3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid supplier Any South Korean citizen returning home who has been in Hubei Province within the past two weeks will be subject to 14 days of self-quarantine and monitoring, the government said. 3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid vendor This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]prop-2-enoic acid factory Any South Korean citizen returning home who has been in Hubei Province within the past two weeks will be subject to 14 days of self-quarantine and monitoring, the government said.